50+ CFO/Controller Best Practices for the Big PictureDoeren Mayhew
Doeren Mayhew Shareholder Juan Padilla shares more than 50 ideas to better manage the CFO/Controller workload so you can play a more strategic, big-picture role in the success of the company.
50+ CFO/Controller Best Practices for the Big PictureDoeren Mayhew
Doeren Mayhew Shareholder Juan Padilla shares more than 50 ideas to better manage the CFO/Controller workload so you can play a more strategic, big-picture role in the success of the company.
Employee Share Schemes & Capital Raising | Wednesdays with Redchip AugustRedchip
Our experts look at two interacting strategies for businesses experiencing, or striving for, high growth:
1. Employee Share Schemes (also known as Employee Share Option Plans) - how do they work and what are the benefits for employers and employees?
2. Capital Raising - how to prepare your business to approach investors and issues to consider in relation to Employee Share Schemes.
DeepOffice is a Philippine-based accounting agency located in Rockwell. We help our clients save on taxes, bookkeeping, financial services, business consulting services.
We can become your online virtual CFO and or accounting agency and help to lower your tax burden whilst helping to manage and manuever your business financial goals.
Contact us today to learn more
Venture capital is a form of startup funding provided to emerging business on the basis of growth prospective of firm in near future.
It involves high risk as the funding is provided to startups which may rise or fall in near future and the probability of getting failed in surviving in the market competitive scenario is higher as compared to rising into a profitable business.
Venture capitalist provides funding on the basis of several factors which indicates a strong ability of firm being successful in business in coming years.
These factors could be an innovative idea, a properly build framework of future business, positive market survey, well - defined business plan etc.
Venture capital is in the form of equity financing where, the investor buys stake or share in the ownership of the company which enables it to share the risk and reward of the business.
Some of the examples of successful start-ups which were highly valued by VCs are :- Uber, Flipkart, Xiaomi, Airbnb
The process goes like-
1.Idea generation stage where the basic idea of business is analyzed in term of its potential
2. Business proposal- this provides a detailed analysis on various factors like market, competitors, plans, financial analysis, set plan, strategies formed etc
3. Meeting- Meeting is held between the owner and venture capitalist after the business proposal is found strong to discuss on future working
4. Agreement- agreement is made regarding the amount of fund to be provided with set terms and condition of holding an equity stake in company
5. Funding- Finally the investment is made by venture capitalists to these start-ups which serves as a form of financing for the business.
Thank You For Watching
Subscribe to DevTech Finance on Youtube to find related videos.
This ppt provides a snapshot on the subject of entrepreneurial finance and also provides an in-depth introduction on venture life cycle and its stages.
Enterslice team helps in Reducing the burden on founders via well defined & Evaluated process, structure, and investor connections. Overall roughly a 1.5 % % hit rate for the companies that pitched in 2015 for Funding.
Capital Raising is also a tremendous time commitment. It is not uncommon to spend 2 to 6 months of nearly full-time effort on a successful venture round.
We can help. We’ve been through the process multiple times; we’ve served as Lead Advisor, Consultant to Founders, Interim CEO or CFO to startup clients that have successfully raised funding.
To know more about our Investment Banking services, please write to info@enterslicellp.com or www.enterslicellp.com
Employee Share Schemes & Capital Raising | Wednesdays with Redchip AugustRedchip
Our experts look at two interacting strategies for businesses experiencing, or striving for, high growth:
1. Employee Share Schemes (also known as Employee Share Option Plans) - how do they work and what are the benefits for employers and employees?
2. Capital Raising - how to prepare your business to approach investors and issues to consider in relation to Employee Share Schemes.
DeepOffice is a Philippine-based accounting agency located in Rockwell. We help our clients save on taxes, bookkeeping, financial services, business consulting services.
We can become your online virtual CFO and or accounting agency and help to lower your tax burden whilst helping to manage and manuever your business financial goals.
Contact us today to learn more
Venture capital is a form of startup funding provided to emerging business on the basis of growth prospective of firm in near future.
It involves high risk as the funding is provided to startups which may rise or fall in near future and the probability of getting failed in surviving in the market competitive scenario is higher as compared to rising into a profitable business.
Venture capitalist provides funding on the basis of several factors which indicates a strong ability of firm being successful in business in coming years.
These factors could be an innovative idea, a properly build framework of future business, positive market survey, well - defined business plan etc.
Venture capital is in the form of equity financing where, the investor buys stake or share in the ownership of the company which enables it to share the risk and reward of the business.
Some of the examples of successful start-ups which were highly valued by VCs are :- Uber, Flipkart, Xiaomi, Airbnb
The process goes like-
1.Idea generation stage where the basic idea of business is analyzed in term of its potential
2. Business proposal- this provides a detailed analysis on various factors like market, competitors, plans, financial analysis, set plan, strategies formed etc
3. Meeting- Meeting is held between the owner and venture capitalist after the business proposal is found strong to discuss on future working
4. Agreement- agreement is made regarding the amount of fund to be provided with set terms and condition of holding an equity stake in company
5. Funding- Finally the investment is made by venture capitalists to these start-ups which serves as a form of financing for the business.
Thank You For Watching
Subscribe to DevTech Finance on Youtube to find related videos.
This ppt provides a snapshot on the subject of entrepreneurial finance and also provides an in-depth introduction on venture life cycle and its stages.
Enterslice team helps in Reducing the burden on founders via well defined & Evaluated process, structure, and investor connections. Overall roughly a 1.5 % % hit rate for the companies that pitched in 2015 for Funding.
Capital Raising is also a tremendous time commitment. It is not uncommon to spend 2 to 6 months of nearly full-time effort on a successful venture round.
We can help. We’ve been through the process multiple times; we’ve served as Lead Advisor, Consultant to Founders, Interim CEO or CFO to startup clients that have successfully raised funding.
To know more about our Investment Banking services, please write to info@enterslicellp.com or www.enterslicellp.com
How to Prepare to Sell or Finance your CompanyTraklight.com
You work hard building up your company to either pass onto family or sell. Maybe you are preparing for your next round of funding. Maximizing your value by discovering all your assets and managing your risk is critical. Hear from experts on how to organize and position yourself for fundraising or exit. Our speakers have been there and done that with fundraising, risk management, executive leadership and outside counsel. Learn tips and tricks from case studies to affordbly spot your risks, cover your assets, and get ready for the next level.
This presentation provides the complete Role and responsibilities of a person acting as a Finance Manager in any XYZ organization.
One can very well use this as a reference to see the basic Job Description for the post of a Finance Manager and can gain meaningful insights from it.
A short presentation on early-stage financing with a primer on how angel investors consider risk and reward for equity investments in high-growth companies at their earliest stages.
Scott droney - financing start-up and growthScott Droney
Scott Droney is provide financial services spectrum as well as data processing and managing segments. Since most of its financial services were retail focused, the need to build scale and skill in the transaction processing domain became imperative.
Beginner's Guide: How to raise Seed and Series A Funding for Your Tech StartupsRakesh Soni
This is a short beginners' guide to learn about startup fundraising particularly Seed and Series A round.
CONTENT:
Introduction
Startup Funding 101:
What is funding and why do you need it?
Types of funding
When to raise and how much to raise
Understanding exit
Key players in fundraising
What matters to founders?
Understanding dilution
How to determine the valuation
Understanding controlling terms
How do VCs work?
Seed and Series A Funding:
Are you ready for funding?
Preparation
How to raise: processes, tips & tricks
Recommended Reading
Q&A
Structuring and Financing a Partner BuyoutGreg Tobben
Buying Out a Business Partner or Shareholder: Structuring and Financing the Deal
When an entrepreneur starts a new business, planning for a buyout of a business partner years in the future is rarely a top priority- but maybe it should be.
As businesses grow and evolve, so too do ownership or shareholder groups. The same partners or investors who took a company from startup to $20 million in revenues aren’t necessarily the right people to grow the company from $20 to $50 million, or $50 to $150 million, and so on.
Layer in retirements, partnership disputes and absentee or non-strategic owners receiving generous compensation, and making changes in ownership becomes increasingly more important (and costly) as the business grows.
On the next few pages, we’ll discuss:
1. When a Partner Buyout is a Solution
2. Valuing the Business
3. Structuring a Partner Buyout
4. Financing a Partner Buyout
5. Questions a Business Owner Should Ask When Raising Capital
6. Using an Investment Banker to Raise Capital for the Buyout
About Access Capital Partners:
Access Capital Partners is a middle market investment bank that provides strategic advisory services, raises capital for companies (growth, refinancing, restructuring, acquisitions, partner buyouts, management buyouts, leveraged buyouts), and helps business owners sell or recapitalization their companies.
We are shareholder centric and have deep experience in the middle market. With over 100 transactions representing over $8 billion in volume, business owners leverage our experience as they navigate through inflection points and ultimately achieve personal liquidity.
Icai national seminar m&a-deal valuationAnjana Vivek
Some pointers on Deal Valuation which is beyond numbers, including some questions 'to trigger thinking' related to valuation from a buyer/seller perspective
Similar to Steve Gordon - Health Sector Business Breakfast (20)
Presentations by Tawfiq Choudhury and Rocco Hadland from the second webinar of the Mastering Cholesterol webinar series on Thursday 11 May 2023, focusing on Statins.
Targeting lipids: a primary and secondary care perspectiveInnovation Agency
Presentations by Dr Sue Kemsley and Dr Gavin Galasko from the first webinar of the Mastering Cholesterol webinar series on Thursday 26 January 2023, focusing on lipid management from a primary and secondary care perspective.
Supporting the optimal detection and management of BP in Primary CareInnovation Agency
Presentation by Jane Briers, Programme Manager - Innovation Agency at the Supporting recovery in Primary Care using Proactive Frameworks for Long Term Conditions event on Thursday 15 September 2022.
Presentation by Dr Lauren Moorcroft, GP Partner - Brookvale Practice at the Supporting recovery in Primary Care using Proactive Frameworks for Long Term Conditions event on Thursday 15 September 2022.
Introduction to Supporting recovery in Primary Care using Proactive Framework...Innovation Agency
Presentation by Julia Reynolds, Associate Director for Transformation - Innovation Agency at the Supporting recovery in Primary Care using Proactive Frameworks for Long Term Conditions event on Thursday 15 September 2022.
Presentation by Paul Brain, Project Manager at the Excel in Health series - Introduction to data webinar on Monday 6 June 2022.
In this session we discussed how SMEs can use data to grow their business and access new opportunities in the market.
Presentations by Mike Kenny, Acting Co-Director of Enterprise and Growth, Innovation Agency and Dr Neil Paul, a GP and Board Member with Cheshire East ICP at the Excel in Health: Understanding the NHS Landscape webinar on Wednesday 11 May 2022.
LCR and Cheshire and Merseyside Health MATTERS networking eventInnovation Agency
Master slide deck from the LCR and Cheshire and Merseyside Health MATTERS networking event on Wednesday 24 November 2021 at Sci-Tech Daresbury Laboratory.
Master slide deck from the Excel in Health webinar series: The NHS landscape presentation.
This webinar identifies the structure of the NHS and its national priorities.
The session will cover the following topics:
Understand the structure of the NHS
Understand the national priorities of the NHS
Recognise the barriers to sale
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
4. PE / VC Option
• The provision of Equity (risk) funding in
return for a stake in the business
• Typical investment package
Ordinary shares – voting
Stake range 15% to 40%
Preference shares – non voting and redeemable over time
Quasi debt which adds to your business without a voting equity cost
Loan stock – usually unsecured but high yield and redemption premium
• Why should I give equity away in my
business
8. Management
• Key criteria: management, management,
management
• Well rounded team including;
~Managing Director
~Finance Director
~Production Director
~Sales Director
~Non-executive director
• Relevant experience
9. Past Performance
• Historic financial information including;
~Profit and loss account
~Balance sheet
~Cash flow
• Commentary on growth
• Explanation for ‘blips’
• Successes
• Strengths
10. Future Performance
• Financial projections
~Profit and loss account
~Balance sheet
~Cash flow
• Sales and marketing strategy
• Analysis of market
• Competitor strategy
12. Vendor concerns
• A 30% to 40% IRR is extortionate!
• Will they take over my company?
• When will they EXIT from the company!
• What is the equity provider looking for?
• Are there limits to the funding available?
• How does the investment process work?
13. Timetable to completion
• Preparation phase (Months 1-2)
~Appoint advisers
~Build financial model
~Write business plan
~Identify appropriate institutions
• Market phase (Months 3-4)
~Attend meetings with institutions
~Negotiate outline terms
~Receive offer (subject to conditions)
14. Timetable to completion (cont)
• Completion phase (Months 5-6)
~Due diligence
~Legal documentation
~Liaison of bankers, accountants and solicitors
~Completion meeting